Health and Healthcare
Valeant Offers Even More for Botox-Maker Allergan
Published:
Last Updated:
Just two days ago Valeant raised its offer by $10 a share, from $48.30 to $58.30. The stock portion has remained constant.
Pershing Square Capital Managment, Allergan’s largest shareholder has agreed to elect only stock in Valeant as payment for its 9.7% stake in the Botox maker. Pershing Square’s CEO, Bill Ackman, has agreed to exchange each of the firm’s Allergan shares for 1.22659 shares of Valeant. Ackman said he called Valeant’s CEO this morning and “offered to give up $600 million of value to other Allergan shareholders and exchange our shares for Valeant stock if Valeant were prepared to increase its offer to other Allergan shareholders.”
Allergan has not responded to Valeant’s offer, but the stock is responding by rising nearly 5% to $166.01 in a 52-week range of $81.33 to $170.05.
ALSO READ: Analysts Stocks to Buy for an Aging America
Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to 3 fiduciary financial advisors in your area in 5 minutes. Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests. If you’re ready to be matched with local advisors that can help you achieve your financial goals, get started now.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.